SPOTLIGHT: Patent bill bogs down
A patent reform bill being argued in Congress has drawn a significant amount of protest from the biotech industry. But with a wide array of groups looking to influence the legislation, including the White House, the bill appears to have stalled in a Senate committee. High-tech companies, meanwhile, have been actively pushing for its passage. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
